Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDAs Must Show Inactive Ingredient Changes Do Not Affect Efficacy - FDA

Executive Summary

Applications for generic drug products with different inactive ingredients than the innovator drug must demonstrate that efficacy is unaffected, FDA said in its proposed rule revising the regulation on bioequivalence/bioavailability and the content and format of abbreviated new drug applications.
Advertisement

Related Content

Bioequivalence Final Rule Requires “Appropriate” Sampling For ANDA Tests
Advertisement
UsernamePublicRestriction

Register

PS033206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel